An Initial Assessment of the Systemic Pharmacokinetics of Botulinum Toxin
- 16 June 2006
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 318 (3), 1343-1351
- https://doi.org/10.1124/jpet.106.104661
Abstract
Botulinum toxin is an extraordinarily potent molecule that has an unusually long duration of action. Despite this, there is little information available on natural mechanisms for metabolism or elimination and virtually no information on pharmacologically induced mechanisms for metabolism and elimination. Therefore, a number of experiments were performed on laboratory animals that addressed two major issues: 1) the effect of blood on the structure, function, and biologic half-life of the toxin, and 2) the effect of neutralizing antibodies on half-life and elimination of circulating toxin. In the first series of studies, the metabolic transformation of toxin was assessed by incubating it in blood for varying lengths of time. At each time point, aliquots were examined to determine the amount of toxin, the structure of toxin, the catalytic activity of toxin, and the neuromuscular blocking activity of toxin. This work demonstrated that blood did not alter any characteristic of the toxin molecule. Experiments were also done in which toxin was administered to mice and rats at doses that produced clinical poisoning. The results demonstrated that the elimination half-life for native (nonmetabolized) toxin in blood and serum was 230 to 260 min. During the second series of studies, the rate of elimination of circulating toxin was studied in the presence of antibodies directed against the carboxyl-terminal half of the toxin molecule. This work demonstrated that neutralizing antibodies 1) enhanced clearance of toxin from the circulation and 2) enhanced tissue accumulation of toxin, particularly in liver and spleen.Keywords
This publication has 32 references indexed in Scilit:
- Human Botulism Immune Globulin for the Treatment of Infant BotulismNew England Journal of Medicine, 2006
- Phosphorylation and Regulation of Psychostimulant-Sensitive Neurotransmitter TransportersJournal of Pharmacology and Experimental Therapeutics, 2004
- Identification of the Major Steps in Botulinum Toxin ActionAnnual Review of Pharmacology and Toxicology, 2004
- The Role of the Interchain Disulfide Bond in Governing the Pharmacological Actions of Botulinum ToxinJournal of Pharmacology and Experimental Therapeutics, 2003
- Sequence homology and structural analysis of the clostridial neurotoxinsJournal of Molecular Biology, 1999
- Immune recognition of botulinum neurotoxin type A: Regions recognized by T cells and antibodies against the protective HC fragment (residues 855–1296) of the toxinMolecular Immunology, 1997
- Therapeutic Uses of Botulinum ToxinNew England Journal of Medicine, 1991
- Clostridium botulinum toxinsPharmacology & Therapeutics, 1982
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970
- The Most Poisonous PoisonScience, 1959